Abstract oral presentations: Session 2

The Scientific Track then returned to the final 3 oral presentations of HAE-related research.

3. Long-Term Prophylactic Treatment with Deucrictibant for Angioedema due to Acquired C1-Inhibitor Deficiency. Dr Mats de Lange, Netherlands, the 2025 HAEi Regional Conference EMEA Young Researcher award recipient

This research investigated a disease estimated to be 10 times rarer than HAE, a form of angioedema in which there is no genetic mutation; instead, the normal bodily response goes wrong, and the levels of C1 inhibitor in patients become too low to prevent swelling attacks. Currently, there is very little clinical research into this condition and its treatment. Dr de Lange’s research trialed the investigational HAE medicine deucrictibant as a preventive treatment for angioedema due to acquired C1-inhibitor deficiency. Their research among 4 patients showed that deucrictibant enabled all patients to achieve total disease control, with 3 of the 4 patients having no attacks during the trial period.

4. Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks in European Participants: Interim Analysis from KONFIDENT-S. Dr Teresa Caballero, Spain

This research examined the effectiveness of a (at the time of presentation) recently approved medication for HAE, sebetralstat. It investigated 69 patients trialing the medicine to treat HAE attacks. In total, the study examined 999 attacks. Dr Caballero showed that symptom relief began at 1.6 hours, severity decreased at 6.8 hours, and complete resolution occurred at 21 hours. There were no serious side effects of treatment. Dr Caballero concluded that the drug resulted in rapid end of progression of attacks, early symptom relief, reduction in attack severity, and attack resolution.

In a subsequent question, Dr Caballero indicated that there were no concerns about taking this oral medication on an empty or full stomach, nor were gastrointestinal side effects likely to be more common.

5. Lanadelumab’s Enduring Impact on HAE Attack Reduction and Improved Disease Control: Final Results from the Enable Study. Prof Andrea Zanichelli, Italy

In the final oral presentation, Prof Zanichelli returned to the stage to present data on the efficacy of lanadelumab in the treatment of HAE. He showed that 138 patients were recruited across 18 sites in Europe and Israel, and the study lasted 2 years. At the end, the authors concluded that patients reported a marked and sustained reduction in attack rate over time. Patients were treated for more than 2 years, but from month 1 onward, the threshold for a patient to consider their disease under control was met and remained so. Prof Zanichelli concluded that the study reinforced the evidence that lanadelumab can be used as a first-line treatment for HAE prophylaxis.